The American Thoracic Society (ATS) has issued a revised set of recommendations for community-acquired pneumonia in adults, according to medonline. The update concentrates on practical clinical questions covering imaging, antibiotic treatment and the use of corticosteroids. The guidance applies to immunocompetent adults.
The revision was reported by medonline on 27 October 2026. The guideline authors are led by Dr. Barbara Jones of the University of Utah in Salt Lake City, medonline reports.
Why it matters
Community-acquired pneumonia is one of the most common reasons adults seek medical care for a lower respiratory infection, and the choices clinicians make at the point of diagnosis shape everything that follows — which tests are ordered, whether antibiotics are prescribed, and whether additional drugs such as corticosteroids are added to treatment.
The ATS update matters because it addresses those everyday decisions directly rather than dwelling on theory. According to medonline, the new recommendations are organized around practice-oriented questions on imaging, antibiotic therapy and steroids, the three areas where clinicians most often face uncertainty.
The guideline also draws a clear line around its scope: it covers immunocompetent adults. That boundary matters for clinicians treating patients whose immune systems are compromised, since the new recommendations are not framed as applying to them.
Clinical signs alone are not enough to confirm pneumonia
A central point in the revised guidance concerns diagnosis. According to medonline, community-acquired pneumonia cannot be reliably distinguished from other lower respiratory tract infections on the basis of clinical presentation alone. Symptoms that suggest pneumonia may overlap with those of other conditions affecting the lower airways, which leaves room for diagnostic error if clinicians rely only on what they observe at the bedside.
To address this, the ATS guideline authors, led by Dr. Jones, call for two elements before a diagnosis is made: symptoms consistent with the condition and imaging evidence of alveolar inflammation. In other words, the clinical picture must be paired with a radiological finding before pneumonia is confirmed.
That requirement has practical consequences. It places imaging at the center of the diagnostic pathway rather than treating it as an optional step, and it gives clinicians a firmer standard for separating pneumonia from other lower respiratory infections. According to medonline, imaging is one of the three subject areas the revised recommendations examine most closely.
Antibiotics and steroids among the questions addressed
Beyond diagnosis, the update takes up treatment. Medonline reports that antibiotic therapy is one of the main themes of the revised guidance, alongside the role of corticosteroids. The guideline is structured around practical questions in these areas, suggesting the authors intended it to offer direction on decisions clinicians make routinely rather than to survey the underlying science.
The focus on corticosteroids reflects a live question in pneumonia care: whether these drugs have a place alongside standard treatment. The ATS recommendations address that question within the framework of the updated guideline, as medonline describes.
The guidance is attributed to the ATS guideline panel headed by Dr. Jones at the University of Utah. Medonline's report does not detail the specific recommendations within each of the three areas, so the precise wording of the advice on imaging, antibiotics and steroids is best consulted in the guideline itself.
What to watch
Clinicians and institutions that manage adult pneumonia cases will be watching how the revised ATS recommendations are taken up in local protocols, particularly the requirement for imaging evidence before diagnosis and the guidance on antibiotic and corticosteroid use.
